Title

SARS-CoV-2 Mediated Hyperferritinemia and Cardiac Arrest: Preliminary Insights

Authors

Prakash VasanthiDharmalingam
Vengadeshprabhu Karuppagounder
Kenichi Watanabe
Harry Karmouty-Quintana
Suresh S. Palaniyandi, Henry Ford HealthFollow
Ashrith Guha
Rajarajan A. Thandavarayan

Recommended Citation

VasanthiDharmalingam P, Karuppagounder V, Watanabe K, Karmouty-Quintana H, Palaniyandi SS, Guha A, and Thandavarayan RA. SARS-CoV-2-mediated hyperferritinemia and cardiac arrest: preliminary insights. Drug Discov Today 2021.

Document Type

Article

Publication Date

1-23-2021

Publication Title

Drug discovery today

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic that began in China, was first noted in December 2019. SARS-CoV-2 infects through the angiotensin-converting enzyme-2 (ACE-2) receptor and co-receptors. In the most severely affected patients, it can cause pneumonia and multiple organ failure leading to death. Reports describe high death rates resulting from cardiac dysfunction, a co-morbid condition in SARS-CoV-2 patients, while the primary cause and mechanisms remain unknown. Here, we attempt to review clinical reports of SARS-CoV-2 patients in order to provide insight into a possible mechanism that allows hyperferritinemia (the presence of excess iron-binding protein) to cause cardiac dysfunction in SARS-CoV-2 patients. Such insights are an important avenue towards understanding the mechanism of cardiac dysfunction in SARS-CoV-2 patients and developing remedies for the same.

PubMed ID

33493677

ePublication

ePub ahead of print